Response to unsolicited enquiries

RNS Number : 0144Z

Hikma Pharmaceuticals Plc

01 March 2013

 



PRESS RELEASE                                                                     

Response to unsolicited enquiries

London, 1 March 2013 - Following the receipt of unsolicited enquiries, Hikma Pharmaceuticals PLC ("Hikma") confirms that it is undertaking a review of strategic options for its Injectables business.

Said Darwazah, CEO of Hikma said "We have received a number of unsolicited expressions of interest in our Injectables business and will consider the best option for shareholders."

A further announcement will be made if appropriate.

-----  ENDS  -----

Enquiries

Hikma Pharmaceuticals PLC

Susan Ringdal, Investor Relations Director                                          [phone]/ 07776 477 050

Lucinda Henderson, Investor Relations Manager                              [phone]/ 07818 060 211

FTI Consulting                                                                                                   [phone]

Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2011, Hikma achieved revenues of $918.0 million and profit attributable to shareholders of $80.1 million. 

 

END

 

 

RSPSSEFSFFDSEED